Technical Analysis for CSPHF - Cstone Pharmaceuticals

Grade Last Price % Change Price Change
B 1.24 -3.88% -0.0500
CSPHF closed down 3.88 percent on Wednesday, December 1, 2021, on 12 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent N/A Down Down
Historical CSPHF trend table...

Date Alert Name Type % Chg
MACD Bearish Centerline Cross Bearish 0.00%
Narrow Range Bar Range Contraction 0.00%
Stochastic Reached Oversold Weakness 0.00%
Wide Bands Range Expansion 0.00%
Gapped Down Weakness 0.00%
Oversold Stochastic Weakness 0.00%
Volume Surge Other -3.88%
Narrow Range Bar Range Contraction -3.88%
Wide Bands Range Expansion -3.88%
Fell Below 20 DMA Bearish -3.88%
Older End-of-Day Signals for CSPHF ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
No Alerts Yet. Alerts will only show here if at least one person is tracking alerts on this stock.
View Earlier Intraday Alerts

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Cstone Pharmaceuticals Description

CStone Pharmaceuticals, a clinical-stage biotechnology company, focuses on developing and commercializing immuno-oncology and molecularly targeted drugs to address unmet medical needs in cancer treatment worldwide. The company's late-stage clinical products include CS1001, a monoclonal antibody against programmed death ligand 1; CS1003, a monoclonal antibody against programmed death receptor; ivosidenib, a potent inhibitor of the mutated isocitrate dehydrogenase-1 enzyme for the treatment of cancer; avapritinib, an inhibitor for the treatment of gastrointestinal stromal tumors and systematic mastocytosis; and Pralsetinib for the treatment of medullary thyroid cancer and other advanced solid tumors. Its products also comprise CS1002, CS3002, CS3003, CS3005, and CS3006 for solid tumors; Fisogatinib that is used for the treatment of hepatocellular carcinoma; and CS3004, CS1009, and CS2004 for other indications. CStone Pharmaceuticals has a licensing agreement with Numab Therapeutics AG for the development and commercialization of NM21-1480, a potential monovalent tri-specific antibody-based molecule targeting PD-L1, 4-1BB, and human serum albumin; a clinical collaboration with Bayer HealthCare LLC to evaluate CS1001 in combination with Bayer's oral multi-kinase inhibitor Stivarga, as a treatment for various types of cancer, including gastric cancer; and a strategic partnership with Burning Rock Biotech Limited to co-develop and commercialize companion diagnostics for pralsetinib, an investigational treatment for the detection of RET alterations in cancer patients. The company was founded in 2015 in Cayman Islands, and is headquartered in Shanghai, China.


Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Medical Specialties Cancer Clinical Medicine Immunology Immune System Solid Tumors Treatment Of Cancer Cancer Immunotherapy Cancer Treatments Monoclonal Antibodies Cancer Treatment Targeted Therapy Hepatocellular Carcinoma Gastric Cancer Medullary Thyroid Cancer Treatment Of Medullary Thyroid Cancer

Is CSPHF a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Recent News

Date Title
Nov 9 CStone Pharmaceuticals and DotBio sign a global discovery collaboration and option agreement to expand emerging portfolio of next-generation innovative therapeutics
Oct 2 CStone presents ARROW study data for GAVRETO® (pralsetinib) in Chinese patients with RET-mutant medullary thyroid cancer (MTC) for the first time in a late breaking oral abstract session at the 90th Annual Meeting of the American Thyroid Association 2021
Sep 15 CStone received China NMPA IND approval for CS2006/NM21-1480, a PD-L1/4-1BB/HSA multi-specific antibody, marking further expansion of its Pipeline 2.0
Sep 14 CStone presents updated data from registrational clinical study of sugemalimab in patients with stage IV NSCLC in an oral presentation at IASLC 2021 WCLC
Sep 9 CStone presents registrational bridging study data for GAVRETO® (pralsetinib) highlighting efficacy and safety in Chinese patients with advanced RET fusion-positive non-small cell lung cancer at IASLC WCLC 2021
Sep 6 CStone Pharmaceuticals Included in the Hong Kong Stock Connect
Sep 2 CStone announces China's NMPA has accepted its new drug application for sugemalimab in the treatment of stage III NSCLC
Aug 20 CStone Pharmaceuticals Selected as a Constituent of HSCI
Jul 26 AYVAKIT® (avapritinib) Companion Diagnostic Test Enters Priority Review and Approval Process in China
Jul 7 CStone announces China NMPA acceptance of IND application for CS2006/NM21-1480, a PD-L1/4-1BB/HSA multi-specific antibody-based molecule, marking further expansion of its Pipeline 2.0 strategy
See more CSPHF news...


Indicator Value
52 Week High 2.6
52 Week Low 0.0001
Average Volume 11,458
200-Day Moving Average 0.0000
50-Day Moving Average 1.5614
20-Day Moving Average 1.6425
10-Day Moving Average 1.6010
Average True Range 0.2730
ADX 10.19
+DI 43.1428
-DI 50.3455
Chandelier Exit (Long, 3 ATRs) 1.6810
Chandelier Exit (Short, 3 ATRs) 1.8190
Upper Bollinger Bands 2.3180
Lower Bollinger Band 0.9670
Percent B (%b) 0.2
BandWidth 82.2527
MACD Line -0.0204
MACD Signal Line 0.0428
MACD Histogram -0.0632
Fundamentals Value
Market Cap 1.45 Billion
Num Shares 1.17 Billion
Price-to-Sales 0.00
Price-to-Book 4.96
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 1.2400
Resistance 3 (R3) 1.2400 1.2400 1.2400
Resistance 2 (R2) 1.2400 1.2400 1.2400 1.2400
Resistance 1 (R1) 1.2400 1.2400 1.2400 1.2400 1.2400
Pivot Point 1.2400 1.2400 1.2400 1.2400 1.2400
Support 1 (S1) 1.2400 1.2400 1.2400 1.2400 1.2400
Support 2 (S2) 1.2400 1.2400 1.2400 1.2400
Support 3 (S3) 1.2400 1.2400 1.2400
Support 4 (S4) 1.2400